ZHANG Xiaohong,DU Ling,GU Weijun, et al. The effects of L-carnitine on patients with fatty liver[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2015, 45(1): 61-.
Abstract：Objective: To investigate the effects of L-carnitine on regulating blood lipids, transaminase, hepatic steatosis and fatty of patients with fatty liver. Methods: Dietary intervention with self-control method was adopted in 32 patients with fatty liver living one community. All participants take plus two oral L-carnitine tablets twice a day for three months. Blood lipids, transaminase, hepatic steatosis and fatty prior to intervention were tested and compared to those of after intervention in all participants. Results: After 3 months’ dietary intervention, ALT, AST, TBIL, TG, TC, LDL of patients were significantly decreased in contrast to those of prior intervention (P<0.01), while HDL was significantly increased (P<0.01). Body weight, body fat index, waistline, abdominal circumference, hips, waist-hip ratio of all participants were decreasing (P<0.01), respectively, meanwhile the subcutaneous fat thickness (arm, back, abdomen) also significantly decreased in contrast to that of prior intervention (P<0.01). Moreover, liver/spleen ratio was significantly increased after intervention (P<0.01), and no side effects was observed in all participants during the trial. Conclusion: As a dietary supplement, L-carnitine can improve the blood lipids, hepatic steatosis, reduce the patient’s transaminase and weight. The dietary intervention strategy is convenient and feasible for patients with fatty liver, and also easy for long-term use.
[1] Shima T, Uto H, Ueki K, et al. Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus[J]. J Gastroenterol, 2013, 48(4): 515-525.
[2] 尹虹. 不同职业者脂肪肝的发病情况及病因分析[J]. 温州医学院学报, 2001, 31(2): 98-99.
[3] 冯文焕, 汪大望, 郑景晨, 等. 罗格列酮对大鼠非酒精性脂肪肝的防治作用[J]. 温州医学院学报, 2006, 36(6): 513-515.
[4] Tang MC, Cheng L, Qiu L, et al. Efficacy of Tiopronin in treatment of severe non-alcoholic fatty liver disease[J]. Eur Rev Med Pharmacol Sci, 2014, 18(2): 160-164.
[5] Guerrerio AL, Colvin RM, Schwartz AK, et al. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease[J]. Am J Clin Nutr, 2012, 95(4): 892-900.
[6] Fedotova AV, Mironova OP, Fedin AI. L-carnitine treatment patients with chronic cerebral ischemia[J]. Zh Nevrol Psikhiatr Im S S Korsakova, 2013, 113(5): 48-53.
[7] Bin Aleem S, Hussain MM, Farooq Y. Levo-carnitine reduces oxidative stress and improves contractile functions of fast muscles in type 2 Diabetic rats[J]. Iran Biomed J, 2013, 17 (1): 29-35.
[8] Miyagawa T, Kawamura H, Obuchi M, et al. Effects of oral L-carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebo-controlled trial [J]. PLoS One, 2013, 8(1): e53707.
[9] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J]. 胃肠病学和肝病学杂志, 2010, 19(6): 483-487.
[10] Kozakova M, Palombo C, Eng MP, et al. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques[J]. Hepatology, 2012, 55(5): 1406-1415.
[11] Hershman DL, Unger JM, Crew KD, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy[J]. J Clin Oncol,2013, 31(20): 2627-2633.
[12] Couce ML, Sánchez-Pintos P, Diogo L, et al. Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: regional experience and high incidence of carnitine deficiency[J]. Orphanet J Rare Dis, 2013, 8(1): 102-107.
[13] Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study[J]. J Gastroenterol, 2012, 47(5): 586-595.
